Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. TME Pharma N.V.
  6. News
  7. Summary
    ALTME   NL0015000YE1

TME PHARMA N.V.

(ALTME)
  Report
Real-time Euronext Paris  -  03:34:33 2023-02-02 am EST
1.170 EUR   +0.26%
01/23Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma
CI
01/20Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities
PU
2022Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TME PHARMA ANNOUNCES PUBLICATION OF ABSTRACT DISCLOSING POSITIVE INTERIM RESULTS FROM BEVACIZUMAB EXPANSION ARM OF NOX-A12 GLORIA PHASE 1/2 BRAIN CANCER CLINICAL TRIAL

11/14/2022 | 09:59am EST

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today publication of the submitted abstract by conference organizers of positive interim data from the GLORIA Phase 1/2 clinical trial expansion arm with NOX-A12 combined with radiotherapy and bevacizumab (biosimilar of Avastin) in first-line MGMT unmethylated brain cancer (glioblastoma) patients.

A poster presentation containing additional and updated data will be presented by Dr. Frank A. Giordano, the principal investigator of the GLORIA study at the Society for Neuro-Oncology (SNO) Annual Meeting on Friday November 18, 2022 starting at 07:30 p.m. EST (01:30 a.m. CET on November 19, 2022) in Tampa, Florida, US.

The interim data from the published abstract show that five out of six patients (83.3%) achieved radiographic partial responses, which remained durable at a median follow-up of 5.6 months (range 3.6 to 9.3 months). Patients with MGMT-unmethylated brain tumors (refractory to chemotherapy) are particularly challenging and respond only rarely to standard of care. The GLORIA data compare favorably to a matched historical reference cohort of 20 glioblastoma patients treated with standard of care, where only 10% of patients achieved partial responses.

In the GLORIA Phase 1/2 brain cancer trial in combination with bevacizumab, the mean best response in tumor size reduction was -65.9% (-13.3% to -99.9%) for sum of target lesion and -92.1% (-76.2% to -100%) for sum of non-target lesions (NTL). In all three patients with NTL, at least one lesion disappeared. Advanced MRI parameters showed reduced blood flow to targeted tumor lesions vs. baseline in all patients, consistent with the anticipated mechanism of action of preventing tumor blood vessel regrowth. Importantly, the neurological function of patients receiving NOX-A12 + RT + bevacizumab remained stable during follow-up as assessed by a scale adapted to patients with brain tumors, the Neurologic Assessment in Neuro-Oncology (NANO) scale.

This abstract presents a brief overview of the status of the ongoing bevacizumab expansion arm of the GLORIA trial from several months ago which strengthens the previously published safety and efficacy profile of NOX-A12,' said Aram Mangasarian, CEO of TME Pharma. 'The data that will be presented at the conference by Dr. Giordano next week on November 18 are more recent and will go into significantly more detail on the follow-up of the patients enrolled in the bevacizumab expansion arm of the NOX-A12 GLORIA trial. I encourage investors interested in better understanding this data to attend the planned webinar on November 22 to hear Dr. Giordano explain the results.'

Contact:

Tel: +49 (0) 30 726247

Email: investors@tmepharma.com

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma's approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial is in discussion with regulatory authorities in the United States and Europe. The company's second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. TME Pharma is considering several solid tumors for further clinical development. Further information can be found at: www.tmepharma.com.

About the GLORIA Study

GLORIA (NCT04121455) is TME Pharma's dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab and C. radiotherapy and pembrolizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma's planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nabpaclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain 'forwardlooking statements.' Forward-looking statements are based on TME Pharma's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma's ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about TME PHARMA N.V.
01/23Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Comb..
CI
01/20Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities
PU
2022Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders
PU
2022Biotech Group TMA Pharma's CFO to Leave by 2022-end
MT
2022Tme Pharma N : announces the resignation of its Chief Financial Officer Bryan Jennings
PU
2022TME Pharma N.V. Announces Executive Changes
CI
2022TME Pharma N.V. Announces the Resignation of Bryan Jennings as Chief Financial Officer
CI
2022Tme Pharma N : The presentation
PU
2022TME Pharma N.V. - POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRA..
AQ
2022TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in ..
CI
More news
Financials
Sales 2021 0,03 M 0,04 M 0,04 M
Net income 2021 -14,5 M -15,8 M -15,8 M
Net cash 2021 7,02 M 7,66 M 7,66 M
P/E ratio 2021 -1,07x
Yield 2021 -
Capitalization 1,59 M 1,73 M 1,73 M
EV / Sales 2020 405x
EV / Sales 2021 316x
Nbr of Employees 13
Free-Float 12,3%
Chart TME PHARMA N.V.
Duration : Period :
TME Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TME PHARMA N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Aram Andrew Mangasarian Chief Business Officer
Maurizio PetitBon Chairman-Supervisory Board
Cornelis Alexander Izeboud Member-Supervisory Board
Martine J. van Vugt Member-Supervisory Board
Susan Coles Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
TME PHARMA N.V.-4.01%2
MODERNA, INC.-2.96%66 963
IQVIA HOLDINGS INC.13.96%43 368
LONZA GROUP AG14.99%42 273
ALNYLAM PHARMACEUTICALS, INC.-4.73%27 670
SEAGEN INC.8.19%25 813